ArticleNature communications2024

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.

J Ricardo McFaline-Figueroa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.